Showing posts with label what is seizure. Show all posts
Showing posts with label what is seizure. Show all posts

Wednesday, August 07, 2013

What should you do if someone has a seizure?

This article details what one can do if one sees someone having a seizure. Remember to call EMS if you have concerns.!

THIS IS A GENERAL INFORMATION article and is not meant to substitute for seeing your dcotor. Always check with your neurologist about specifics for you or your child.  JR




If a friend, family member or co-worker has epilepsy, you should know what to do if he or she has a seizure.
Once a seizure begins, nothing can be done to make it end more quickly. But you can take steps to prevent seizure victims from hurting themselves:
  • Move furniture and sharp objects away from the victim.
  • Should the victim vomit, turn his or her head to the side so he or she does not choke.
  • If the victim is unconscious, make sure nothing is obstructing the nose or mouth.
After a seizure ends, most people sleep deeply. Do not try to prevent this deep sleep. Once the victim awakens, he or she may be disoriented for a while.

Be sure to stay with the victim until he or she recovers fully, or until emergency medical help arrives. Also, keep an eye on the victim’s breathing rate and pulse.
Do not do the following things for a seizure victim. You will risk hurting the seizure victim and yourself:
  • Do not restrain someone having a seizure.
  • Do not put a spoon, tongue depressor or anything else in his or her mouth, especially not your fingers. It is a myth that seizure victims can swallow their tongues.
  • Do not move the victim unless he or she is in immediate danger or near a hazard.
  • Do not perform artificial respiration during a seizure, even if the victim is turning blue. Most seizures are over long before brain damage from lack of oxygen begins. However, if a seizure lasts longer than two minutes, call for emergency medical help.
  • Do not give the victim food, drink or medication by mouth until the seizure has stopped and he or she is completely awake and alert.
Call immediately for emergency medical help for someone who:
  • has seizures lasting longer than two minutes or has more than one seizure per hour
  • does not wake up between two seizures
  • is injured, ill or intoxicated
  • has a seizure for the first time
  • is pregnant or has diabetes or high blood pressure
  • has a seizure in water
After other seizures, call the seizure victim’s healthcare provider.
Read more here

Thursday, October 25, 2012

Study: Prenatal antibiotics linked to high risk of epilepsy

A study claims that taking a specific type of antibiotic during pregnancy could increase the risk of epilepsy in their children.


A new study in Pediatric and Perinatal Epidemiology suggests that taking cystitis antibiotics during pregnancy increases risk of epilepsy in children.

J. E. Miller of School of Public Health, University of California, Los Angeles, CA and colleagues conducted the study and found taking cystitis antibiotics during pregnancy was associated with 10 to 20 percent increased risk of epilepsy in children.

For the study, researchers followed all liveborn singletons (447,629 children) born in Denmark between Jan 1996 and Sept 2004 for as long as 9.9 years.  A total of 2,848 children were diagnosed with epilepsy during the follow-up.

Cystitis antibiotics included pivmecillinam, sulphamethizole and nitrofurantoin. 

Children born to mothers who had redeemed prescriptions during pregnancy for pivmecillinam, sulphamethizole, and nitrofurantoin were 20%, 20% and 10% more likely to develop epilepsy, compared to those born to mothers who did not use antibiotics during pregnancy.

After adjustment for  other factors, among mothers with multiple redeemed prescriptions during pregnancy, those taking pivmecillinam or sulphamethizole  or nitrofurantoin were each associated with 30 percent increased risk of epilepsy in their children.

Read more here

Wednesday, October 24, 2012

Greater Costs, Morbidity Among Uncontrolled Epilepsy Patients


An intersting article about the costs of poorly controlled epilepsy - JR

Greater Costs, Morbidity Among Uncontrolled Epilepsy Patients

By: TARA HAELLE, Clinical Neurology News Digital Network

10/23/12 


VITALS

Major Finding: Compared with patients with well-controlled epilepsy, patients with uncontrolled epilepsy have 1.9-2.2 times more fractures and head injuries, receive 1.3-1.9 times more prescriptions, are hospitalized 5.4-6.7 times more often, are admitted to emergency departments 3.7-5 times more often, and incur $12,258-$14,582 greater annual health care costs.


Patients whose epilepsy was uncontrolled had more injuries, spent more time in the hospital, received more prescriptions, and incurred greater health care resource usage and costs than did patients whose epilepsy was under control in a retrospective, longitudinal matched-cohort study.
Additionally, uncontrolled epilepsy in private insurance patients incurred nearly $2,900 more in work time lost for disability and sick leave, comprising about one-fifth of these patients’ total direct health care costs.

Lead author Ranjani Manjunath of GlaxoSmithKline and her associates analyzed public and private insurance claims to determine how health care resource utilization and costs and epilepsy-related injuries differed between patients with uncontrolled epilepsy and those with well-controlled epilepsy. The findings were reported online Oct. 17 (Neurology 2012;79:1908-16).

The researchers defined patients with uncontrolled epilepsy as those who had at least two consecutive changes in their antiepileptic drug (AED) regimen (at least a month apart) and at least one subsequent hospitalization or emergency department visit within the next year. Patients taking AEDs but who had no changes in their therapy as well as no hospitalizations or ED visits were defined as having well-controlled epilepsy.

A total of 3,454 Medicaid patients and 602 private insurance patients with uncontrolled epilepsy were matched 1:1 with well-controlled epileptic patients for the study. Propensity score matching was used to reduce sample selection bias, and adjusted risk ratios for outcomes took into account age, sex, state or region, baseline AED use, use of other drugs known to increase seizure risk, baseline costs, and psychiatric conditions or epilepsy-related comorbidities (Alzheimer’s disease, brain tumor, meningitis, migraine, and stroke). A lower percentage of uncontrolled epilepsy patients were using AEDs at baseline: 48.1% of uncontrolled Medicaid patients, compared with 52.6% of well-controlled Medicaid patients (P less than .001), and 40% of uncontrolled private patients, compared with 45.5% of well-controlled private patients (Pless than .05).

...

The researchers selected only adult patients who had a prescription for an AED and who had been diagnosed with epilepsy or diagnosed with two nonfebrile seizures more than a month apart. All patients had been enrolled in their insurance plan for at least a year, and baseline included the 180 days before the patient’s first AED prescription. Patients were tracked until death, the end of continuous enrollment, or the end of the period for which data were available.

The study found that Medicaid and private patients with uncontrolled epilepsy had similarly higher incidence rate ratios (incidence rate defined as events divided by patient-years) of injury with 1.9-2.2 times more fractures and head injuries. 

Medicaid patients had 2.45 times more car accident injuries and 10 times more status epilepticus episodes.

Compared with patients who had well-controlled epilepsy, Medicaid patients had 1.94 times more AED prescriptions, 1.47 times more non-AED prescriptions, 6.65 times more hospitalizations, 7.72 times more days in the hospital, 3.67 times more ED visits, 1.66 times more outpatient services, and 3.09 times more neurologist visits. 

Likewise, private patients received 1.75 times more AED prescriptions, 1.34 times more non-AED prescriptions, 5.37 times more hospitalizations, 7.27 times more days in the hospital, 5.05 times more ED visits, 1.41 times more outpatient services, and 2.28 times more neurologist visits. (All P values were less than .05.)

Overall, Medicaid patients with uncontrolled epilepsy incurred an average $12,258 more in costs than Medicaid patients with well-controlled epilepsy, and uncontrolled epileptic private patients’ total extra cost was $14,582. 

Most of these costs came from hospitalization; outpatient services and prescription drugs comprised the next largest share. Private patients also missed 2.5 times more workdays, including 61% more sick days.

Saturday, October 13, 2012

Epilepsy & Global Health - A New Priority

An article from BBC discusses how epilepsy is turning into a global health issue.

Epilepsy is twice as common in low and middle-income countries as it is in the developed world, according to an international team of researchers.

They say the higher incidence is linked to increased risk factors, including head injuries and infections such as pork tapeworm and river blindness.

And more than 60% of sufferers in those countries receive no appropriate treatment, they say in the Lancet.

A Lancet editorial said epilepsy had to be a global health priority.
Epilepsy is a condition in which disturbances to the brain's normal electrical activity cause recurring seizures or brief episodes of altered consciousness.
There are about 40 different types. Epilepsy is not a mental illness, but can develop after injury or damage to the brain.
About 85% of the global burden of epilepsy occurs in low and middle-income countries.
'Bewitched'
Writing in the Lancet, researchers led by Prof Charles Newton, of the University of Oxford, say the death rate in developing countries is much higher than in developed ones - and that the reason for this is likely to be a failure to treat people with the condition.
Prof Newton said: "The burden of epilepsy in these regions is at least double that found in high-income countries, and sadly, adequate facilities for diagnosis, treatment and ongoing management of epilepsy are virtually non-existent in many of the world's poorest regions."
He added: "Many people with epilepsy or their families do not even know that they have a disorder that can be controlled with biomedical treatment, so it is vitally important that awareness is raised and medical care improved in these regions."
Medications are available - but there can be problems distributing them, especially to remote areas.
The researchers say there are low-cost ways of improving the situation and of reducing the stigma often faced by people with epilepsy and their families - such as working with traditional healers and awareness campaigns to increase understanding of the condition.
In some countries, traditional beliefs about the causes of the condition, including bewitchment, spiritual causes and curses, lead to stigma and increase the chance that a person with epilepsy will not get the treatment they need.
A Lancet editorial adds: "Given the prevalence of epilepsy globally, it should be included as a priority on the public health agenda, and access to treatment should be greatly improved in developing countries.
"It is time for all governments to take epilepsy more seriously."
Read more here

Dr. Rotenberg to speak at Houston Epilepsy Foundation Conference

  

2012 Family Conference


November 10, 2012

Toyota Center

Houston, Texas


Registration
2:00 p.m.

Session I
3:00 p.m.
Parent Track: Dr. Rotenberg- Seizures and Sleep
Adult Track: Maria Palacios- Living Well with Epilepsy

Session II
4:00 p.m.
Parent Track: Mary Jane Williams- IEP and ARD Overview
Adult Track: Dr. Hartshorn- Medical Management

Session III
5:00 p.m.
Parent Track: Dr. Wilfong- New Treatment & Surgery Options
 
Adult Track: Dr. Kalamagalam- 
New Treatment & Surgery Options

Dinner
6:00 p.m.
Houston Rockets vs. Detroit Pistons
7:00 p.m.

Activities will be provided for children 
ages 6-13 years during the conference

**Parking is not included in the ticket price. 
Participants are responsible for their own parking 
at the Toyota Center**

Contact Heather at hpena@eftx.org
or 888-548-9716 or 713-789-6295 with any questions. 



Wednesday, October 03, 2012

This article discusses the impact of epilepsy in developing countries and how it is often overlooked.
The burden of epilepsy in poorer parts of the world could be readily alleviated by reducing the preventable causes and improving access to treatment, according to a review article published September 27 in the Lancet.
The researchers call for greater recognition from international and national health agencies to address the management of epilepsy in the developing world.
Despite being one of the most cost-effective disorders to treat, there are twice as many people living with epilepsy in low- and lower-middle-income countries than higher income nations and more than 60% of those affected in these regions are not accessing any appropriate treatment.
Lead author Professor Charles Newton, who works in the Wellcome Trust programmes in Tanzania and Kenya, said: "Epilepsy needs to be brought into the agenda of non-communicable diseases. It was not mentioned in the UN General Assembly Meeting in New York to address the global burden of non-communicable diseases, and yet it represents a substantial burden of ill health."
Epilepsy is a common disorder, particularly in poor areas of the world, but deriving accurate figures on the epidemiology of epilepsy in low- and lower-middle income countries is very difficult. There have been very few surveys to gather appropriate data and such studies tend to be expensive, especially for countries whose health research funding is likely to be very limited.
Professor Newton and Professor Hector Garcia, both Wellcome Trust Senior Research Fellows, conducted a comprehensive review of academic articles about epilepsy in developing countries in order to piece together a picture of the burden of the disease in poorer parts of the world.
They conclude that the high number of people with epilepsy in these regions is likely caused by the higher incidence of risk factors, such as head trauma, complications during childbirth, and parasite infections such as pork tapeworm (neurocysticercosis), and river blindness (onchocerciasis).
The study also reveals the enormity of the treatment gap in poorer nations, with over 60% of people living with epilepsy in low- and lower-middle-income countries not accessing appropriate care. This is partly due to poor adherence to prescribed treatment but there remain huge barriers to accessing care, particularly in rural areas. The stigma associated with the disorder and cultural beliefs around causation is identified as a major problem, along with distance from a health-care facility and inadequate skilled manpower.
The epilepsy burden could be easily reduced by addressing some of the risk factors, say the authors. They highlight several ways in which epilepsy care could be improved at low cost, including by engaging traditional healers who for many people are the only point of care for epilepsy. Given the lack of expertise in management of epilepsy in poorer areas, they suggest that neurologists and psychiatrists should combine to set up services for the management of epilepsy in these regions.
"Sadly, adequate facilities for diagnosis, treatment and on-going management of epilepsy are virtually non-existent in many of the world's poorest regions. Many people with epilepsy or their families do not even know that they have a disorder that can be controlled with biomedical treatment, so it is vitally important that awareness is raised and medical care improved in these regions," added Professor Newton.
Read more here

Tuesday, October 02, 2012

Effect of Treatment of Obstructive Sleep Apnea on Seizure Outcomes in Children With Epilepsy


Besides medicine, what else can you do to reduce seizures in children? Check their sleep! JR

Effect of Treatment of Obstructive Sleep Apnea on Seizure Outcomes in Children With Epilepsy

Department of Neurology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts
Received 22 October 2011; accepted 8 March 2012.

Abstract 

A retrospective review of children with epilepsy and obstructive sleep apnea, treated surgically for their obstructive sleepapnea from January 2008-October 2010, was performed for age, sex, type of epilepsy, antiseizure medications, sleep-study data, and changes in seizure frequency. Twenty-seven subjects (median age, 5 years) with no adjustment to their medications around their time of surgery were identified. Three months after surgery, 10 (37%) patients became seizure-free, three (11%) demonstrated >50% seizure-reduction, and six (22%) exhibited an amelioration of seizure frequency. Two (7%) demonstrated unchanged seizure-frequency, and six (22%) manifested a worsening of seizure frequency. Median seizure frequency before surgery was 8.5 (interquartile range, 2-90), and after surgery, three (interquartile range, 0-75), with a 53% median seizure reduction. Multivariate analysis demonstrated a trend toward seizure freedom with each percentile increase in body mass index and early age of surgery. We conclude that obstructive sleep apnea surgery may decrease seizure frequency, especially in children with elevated body mass index scores and younger age at time of surgery.

Headset that Treats Epileptic Seizures?

Headset that Treats Epileptic Seizures? 

Another new "neuroprosthetic" reaching overseas patients. JR

A new headset over a number of years has shows a 60% decrease in epileptic seizures for some epileptic patients.

A small electrical headset that works during sleep could help to treat patients with major depression and severe epilepsy.

The device takes the form of two square, sticky pads attached to either side of the forehead, just above a major nerve in the brain. 

These pads are attached by wires to a small box the size of a mobile phone that sits at the waist. It generates a small electrical pulse that lasts 30 seconds and is followed 30 seconds later by another pulse.

The pulses stimulate the trigeminal nerve and can reduce the number and severity of epileptic seizures as well as combating depression.

Studies have shown that a small number of severely epileptic patients who used the gadget for a year saw their number of seizures drop by an average of 60 per cent.

Meanwhile, tests on people with major depression saw their scores on the Beck Depression Inventory,  a scale used to rank depression, improve significantly.

The procedure, called Trigeminal Nerve Stimulation, was created by a team of neurologists at the University of California.

Their device, known as Monarch, was then developed by the medical devices firm Neurosigma and has now been approved for use in Europe after pilot studies showed it could provide an additional treatment for patients with depression and epilepsy.

It would normally be used in conjunction with drugs to treat patients whose seizures cannot be controlled by medicine alone.

Although experts are still not clear as to exactly why stimulating the trigeminal nerve reduces seizures and depression, it is the latest in a series of stimulation devices. However, this one is exciting doctors and patients because it does not require surgery.

Monarch will be made available in the UK privately within the next few months and will eventually be assessed for use on the NHS.

Epilepsy affects 600,000 people in Britain and only around half are seizure-free.

Read more here

Sunday, September 23, 2012

Scientists Discover Biological Mechanism That Triggers Epileptic Seizures

Scientists have found a biological mechanism that is capable of causing seizures. This is an important discovery for both therapies and future research.

Scientists have discovered the first direct evidence that a biological mechanism long suspected in epilepsy is capable of triggering the brain seizures -- opening the door for studies to seek improved treatments or even preventative therapies.

Researchers at Cincinnati Children's Hospital Medical Center report Sept. 19 in Neuron that molecular disruptions in small neurons called granule cells -- located in the dentate gyrus region of the brain -- caused brain seizures in mice similar to those seen in human temporal lobe epilepsy. The dentate gyrus is in the hippocampus of the temporal lobe, and temporal lobe epilepsy is one of the most common forms of the disorder.
"Epilepsy is one of those rare disorders where we have no real preventative therapies, and current treatments after diagnosis can have significant side effects," said Steven Danzer, PhD, principal investigator on the study and a neuroscientist in the Department of Anesthesia at Cincinnati Children's. "Establishing which cells and mechanisms are responsible for the seizures allows us to begin working on ways to control or eliminate the problem therapeutically, and in a more precise manner."
Epilepsy can develop from a wide range of causes, including birth defects in children that disrupt normal brain development. It can also surface in children and adults who suffer serious brain injuries. These individuals can have high risk of developing some form of epilepsy, depending on the location and severity of their injury, Danzer said.
Technical advances in genetically altering laboratory mice to mimic human disease made it possible for the scientists to generate animals with a specific molecular disruption in dentate gyrus granule cells (DGCs). DGCs are one of only two populations of neural cells that continue to form in significant numbers in the mature brain -- the other being olfactory neurons. This is beneficial considering the hippocampus is responsible for learning and memory, and the dentate gyrus acts as a gate for excitatory signals in the brain that can lead to seizures if not properly regulated.
The presence of abnormal DGCs in epilepsy has been observed for decades, although evidence linking them to seizures was lacking until the current study. Danzer and his colleagues were able to delete a gene called PTEN from mouse DGCs that formed after birth. This caused hyper-activation of a molecular pathway called mTOR (mammalian target of rapamycin), which regulates cell growth and is also linked to tumor formation and cancer when hyper-activated under certain circumstances.
In tests by Danzer and his colleagues, hyper-activation of mTOR caused mice to develop abnormal neural connections among their DGCs -- similar to that observed in human temporal lobe epilepsy -- and the animals experienced seizures. Abnormal neural connections and seizures occurred even in mice that had the PTEN gene deleted in less than 10 percent of their total DGC population, strengthening the link between biological disruption of DGCs and seizures.
When researchers treated epileptic mice with a drug that blocks the mTOR pathway -- rapamycin -- the seizures stopped, solidifying the link to the PTEN-mTOR pathway. Rapamycin has been tested successfully at Cincinnati Children's in the treatment of a disease called tuberous sclerosis, in which benign but still dangerous tumors can form around critical organs. Interestingly, people with tuberous sclerosis are also at risk for developing epilepsy, Danzer said. Newer mTOR inhibitors are also being tested at Cincinnati Children's for the treatment of epilepsy.
Danzer is following up the current study by trying to eliminate abnormal DGCs from the brains of mice that already have epilepsy and to see if this will stop the seizures. Researchers are attempting this by treating mice systemically with diphtheria toxin.
Although diphtheria toxin is not normally toxic to mouse cells, in their experiments the researchers will add a molecule to abnormal mouse DGCs that binds with the toxin. In theory, this should allow the toxin to kill off abnormal DGCs. If treatment stops the seizures, it would further verify the connection between abnormal DGCs and the onset of epilepsy, Danzer said. This would also allow researchers to begin laboratory testing of prospective therapeutic strategies for treatment and prevention.
Mutations involving PTEN and the mTOR pathway have also been identified in other neurological conditions, such as autism and schizophrenia. Danzer said findings in the current study will likely attract the interest of researchers studying these diseases and others involving abnormal granule neurons generated after birth.
"The profound impact of disrupting this pathway in just a small number of granule cells suggests the dentate may be a critical target for mTOR pathway mutations in other neurological diseases," Danzer said. "We believe neuroscientists will be surprised by the huge neurological impact of granule cell disruption and interested in the demonstration of a potentially novel disease mechanism."

Read more here

Tuesday, September 18, 2012

A drug company plans to use a form of cannabis in a drug trial to treat epilepsy.


A British drug company aims to test a compound found in cannabis as a treatment for epilepsy, following a promising study using the chemical in rats and mice.

GW Pharmaceuticals said on Thursday that human clinical trials using cannabidivarin (CBDV) could start in 2013 after University of Reading scientists reported the previously little-studied chemical had potential as an anticonvulsant.

CBDV is one of many non-psychoactive cannabinoids found in the cannabis plant and does not cause users to feel ‘high'.

The pre-clinical tests carried out by Ben Whalley and colleagues at Reading found that rats and mice with induced seizures who were given the compound had less severe attacks than those on a placebo. CBDV was also found to work when combined with drugs currently used to control epilepsy.

Nomura Code industry analyst Samir Devani said the data was encouraging but the research was still very early stage.
Experts noted that the rats and mice in the study were made epileptic, which is not how the disease occurs in humans, and positive results in animals often do not translate into similarly good results in people.

Whalley's work was funded by, and performed in collaboration with, GW and its partner Otsuka Pharmaceuticals. The two drug companies have a global alliance on cannabis research.

GW has already commercialized one cannabis-derived drug called Sativex, an under-the-tongue spray that is on the market for treating spasticity associated with multiple sclerosis. Sativex is also in late-stage development for cancer pain.


Read more here

Monday, September 17, 2012

Surgeon claims King Tutankhamen died from epilepsy

An interesting theory explaining why a british surgeon believes King Tutankhamen died from epilepsy.


Ever since King Tut’s lavish tomb was opened in 1924, when people weren’t muttering about the curse supposedly placed on it they were trying to divine what killed the young Egyptian king. Now, a British surgeon and history buff has a new theory about not only what may have caused King Tut’s death, but also led Egypt to become the world’s first monotheistic culture.
Hutan Ashrafian, a surgeon at Imperial College London, thinks the malady that killed King Tut was epilepsy. Ashrafian’s theory, reported in New Science, is the result of some good old fashioned historical deduction. The surgeon noted the pharaohs’ feminized figures, as they appeared in the artistic portrayals of King Tut and his presumed relatives — Smenkhkare, believed to be Tutankhamun’s uncle or older brother, and Akhenaten, who is thought to be Tut’s father. He also took into account findings that each pharaoh had died at a slightly younger age than his predecessor. To Ashrafian, this suggested an inherited disorder. Then Ashrafian looked at the religious events that occurred under these pharaohs’ watch.  “It’s significant that two [of the five related pharaohs] had stories of religious visions associated with them,” Ashrafian told New Science. The religious experience of Tuthmosis IV is inscribed near the Great Sphinx, while Akhenaten’s religious vision encouraged him to raise the status of a minor deity called Aten into a supreme god — thus establishing the earliest recorded monotheistic religion.
For Ashrafian, this historical milestone was another clue to what may have killed boy king. “People with temporal lobe epilepsy who are exposed to sunlight get the same sort of stimulation to the mind and religious zeal,”  Ashrafian told the Washington Post. “It’s likely that the family of pharaohs had a heritable form of temporal lobe epilepsy.” According to New Science, the temporal lobe is connected to parts of the brain involved in the release of hormones, and epileptic seizures are known to alter the levels of hormones involved in sexual development — which could explain why the pharaohs were depicted with wide hips and larger breasts than you would expect on a man. A seizure might also be to blame for Tutankhamen’s fractured leg, says Ashrafian — evidence of which had led some to speculate that Tut died from injuries sustained after a fall from his chariot.
But the new theory does not completely lay to rest speculation about the cause of death of King Tutankhamen. “It’s a fascinating and plausible explanation,” said Howard Markel, a medical historian at the University of Michigan in Ann Arbor, to the Washington Post. However, he notes, the theory is almost impossible to prove, given that there is no definitive genetic test for epilepsy. “Do we know that a seizure led to monotheism? It’s a nice idea, but we don’t know,” he says. “It’s a very interesting hypothesis, but it’s just that — there’s no definite proof.”
Read more here

Saturday, September 15, 2012

Researchers find more Autism Genes


Its news like this that keeps me going. Every day, I meet parents who have given up on neurology.  Even in the last 5 years, our tools for diagnosis and treatment have changed. With advances in genetics more news will come. - JR 

Researchers at UCSD found a gene that indicated autism associated with epilepsy.

A genetic cause for a rare form of epilepsy-associated autism has been identified by UC San Diego and Yale scientists.
Moreover, symptoms of the newly discovered form have been reversed in mouse models by altering diet. This gives rise to the possibility that similar treatment might help people, the researchers said. The study was published online Thursday in the journal Science
Researchers led by Gaia Novarino and Joseph G. Gleeson of UCSD studied two families, one of Egyptian descent and another of Turkish origin. They examined the genome of patients and healthy relatives for exons, gene sequences that code for proteins. The researchers found that patients shared an exon mutation on a gene called BCKDK. The mutant gene is recessive, meaning that it must be inherited from both mother and father to manifest.
Moreover, the researchers found that the mutation caused patients to produce abnormally low levels of certain types of amino acids, the building blocks of proteins. They were able to boost levels of these amino acids to normal with a nutritional supplement from a health food store. Research is now ongoing as to whether this supplementation will reduce symptoms of epilepsy and autism in these patients.
Those who might be helped are only a small fraction of people with autism, Novarino said in an Tuesday interview. Those without the metabolic defect wouldn't benefit from the supplementation.
The study illustrates how scientists have become more sophisticated in using knowledge of the human genome to crack the puzzle of previously intractable diseases. The genome is the complete set of hereditary information encoded in DNA.
Narrowing the search
The vast majority of DNA does not code for proteins, the body's workhorse molecules. This "non-coding" DNA was ignored in the new method of DNA analysis, called "whole exome" sequencing, which looks only at the exons. An advantage of whole exome sequencing is that it focuses exclusively on proteins, which are altered or missing in genetic diseases.
Whole exome sequencing can find previously undiscovered genetic diseases, according to another study performed by some of the same UCSD researchers. They examined 118 patients diagnosed with neurological disorders who had no known genetic disease causes. In addition to the newly discovered genetic causes, in about 10 percent of cases the researchers even found a known disease-causing gene that had previously escaped detection.
That study was published in June in Science Translational Medicine, a journal devoted to getting research discoveries into the hands of doctors more quickly.
The new study is part of the same project of applying exome research to diseases, Novarino said.
Genetic knockout
In the study, the researchers produced genetically engineered "knockout mice" in which the BCKDK gene was inactivated. These mice experienced epileptic seizures, tremors, hind limb clasping and other symptoms of neurological disorders. Their brains were found to be deficient in certain chemicals called branched chain amino acids.
Seizures and hind limb clasping were "completely abolished" within a week when mice were given diets rich in these nutrients, the study said.
The researchers had previously examined neural cells of patients and unaffected family members. The neural cells were made from induced pluripotent stem cells, produced from skin cells and turned into neurons. However, the researchers couldn't find any differences in the cell cultures. That's when they turned to studying the effect of diet on whole knockout and healthy mice.
Novarino said it's too early to tell if BCAA supplementation is helping the human patients in the study.
The supplements have not caused any side effects in the patients, nor did they in the mouse, Novarino said.
The complete list of authors, including colleagues in Turkey, Egypt and Libya, can be found at the end of the press release. Funders of the study include the National Institutes of Health, the Center for Inherited Disease Research, and the Simons Foundation Research Initiative.
Read more here